{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"Change in magnetic resonance imaging (MRI) from baseline to evaluation at 6 weeks for participants where MRI changes are based on the size of edema (T2 FLAIR) and Gd-contrast enhancement (lesion diameter and perfusion/dynamic). A 25% reduction in T2 flair volume constitutes a response for study.","groups":[{"description":"Bevacizumab 7.5 mg/m\\^2 intravenous (IV) every 3 weeks","id":"OG000","title":"Arm A: Bevacizumab"},{"description":"Placebo IV every 3 weeks for two courses, crossover at 6 weeks to receive Bevacizumab 7.5 mg/m\\^2 IV as in Arm A","id":"OG001","title":"Crossover Arm B: Placebo Then Bevacizumab"}],"paramType":"NUMBER","populationDescription":"Analysis was conducted per protocol. The participants in the Crossover Arm were evaluated after receiving the Bevacizumab treatment as described in the arm description.","reportingStatus":"POSTED","timeFrame":"Baseline to 12 weeks","title":"Number of Participants With Response ( > 25% Reduction in T2 Flair) From Baseline to Evaluation at 6 Weeks Post Treatment","type":"PRIMARY","unitOfMeasure":"participants"}